June 24, 2025

Fasting Triggers Inflammation, Platelet Activity, Metabolic Shift 

A human fasting study found that prolonged water-only fasting raised inflammatory and platelet activation markers, reduced amyloid beta proteins, and altered lipid and glucose metabolism, with most changes reversing after refeeding.

Conexiant

June 24, 2025

Do CBC Ratios Predict RA Mortality?

Elevated SIRI, NLR, and MLR from routine blood counts independently predicted higher all-cause mortality among patients with rheumatoid arthritis.

Conexiant

June 24, 2025

Barium and Psoriasis: Emerging Mechanistic Link

A mini-review explores how environmental barium may disrupt immune signaling pathways associated with T-cell activation and keratinocyte proliferation.

Conexiant

June 24, 2025

Is T1b Diabetes Often Genetic?

A review of nearly 300 idiopathic diabetes cases found that about 30% of patients had undiagnosed genetic mutations, raising concerns about misclassification and underuse of comprehensive genetic testing.

Conexiant

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 23, 2025

What’s the Dose for Hair Regrowth?

A national survey found wide variation in intralesional corticosteroid injection techniques among US hair specialists treating different types of alopecia.

Conexiant

June 23, 2025

STING Deletion Attenuates Amyloid Beta Pathology

Genetic deletion of STING in a mouse model of Alzheimer’s disease reduced amyloid plaque accumulation, suppressed neuroinflammatory responses, and improved memory, highlighting STING’s role in disease progression and potential as a therapeutic target.

Conexiant

June 23, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

June 23, 2025

Methotrexate Adds No Psoriasis Benefit to Adalimumab

The addition of methotrexate to adalimumab for the treatment of plaque psoriasis may not improve drug survival, efficacy, or safety compared with adalimumab alone, according to a large real-world cohort study.

Conexiant